海昇药业
(920656)
| 流通市值：0.00万 | | | 总市值：0.00万 |
| 流通股本：0.00万 | | | 总股本：0.00万 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 100,845,726.94 | 41,982,766.72 | 166,209,055.55 | 116,290,891.37 |
| 营业收入 | 100,845,726.94 | 41,982,766.72 | 166,209,055.55 | 116,290,891.37 |
| 二、营业总成本 | 68,348,075.9 | 28,758,458.48 | 117,608,153.68 | 79,543,652.56 |
| 营业成本 | 57,083,261.2 | 24,173,159.05 | 99,745,346.32 | 69,646,871.23 |
| 税金及附加 | 981,041.41 | 137,835.34 | 1,933,600.88 | 973,928.77 |
| 销售费用 | 1,461,487.18 | 350,806.23 | 2,174,544.68 | 1,715,601.14 |
| 管理费用 | 4,309,443.78 | 1,814,465.87 | 9,982,647.75 | 7,414,444.7 |
| 研发费用 | 5,208,687.53 | 2,693,987.3 | 9,577,097.56 | 6,151,349.94 |
| 财务费用 | -695,845.2 | -411,795.31 | -5,805,083.51 | -6,358,543.22 |
| 其中:利息收入 | 659,849.44 | 287,558.63 | 4,591,112.38 | 5,669,461 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 2,713,798.71 | 1,573,001.46 | 4,877,691.2 | - |
| 资产减值损失(新) | -5,028.7 | 29,125.97 | -371,424.8 | - |
| 信用减值损失(新) | -877,424.21 | 65,850.11 | 712,447.27 | 620,585.27 |
| 其他收益 | 635,004.63 | 339,314.82 | 4,502,946.13 | 920,092.88 |
| 四、营业利润 | 34,964,001.47 | 15,231,600.6 | 58,322,561.67 | 38,287,916.96 |
| 加:营业外收入 | 19,800 | 4,000 | 71,639.83 | 4,605 |
| 减:营业外支出 | 250 | - | 40,300 | - |
| 五、利润总额 | 34,983,551.47 | 15,235,600.6 | 58,353,901.5 | 38,292,521.96 |
| 减:所得税费用 | 4,657,644.49 | 1,974,696.75 | 7,603,678.1 | 4,963,159.67 |
| 六、净利润 | 30,325,906.98 | 13,260,903.85 | 50,750,223.4 | 33,329,362.29 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 30,325,906.98 | 13,260,903.85 | 50,750,223.4 | 33,329,362.29 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 30,325,906.98 | 13,260,903.85 | 50,750,223.4 | 33,329,362.29 |
| 扣除非经常损益后的净利润 | 27,865,242.89 | 11,893,977.21 | 43,534,755.05 | 32,923,964.3 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.3 | 0.17 | 0.65 | 0.43 |
| (二)稀释每股收益 | 0.3 | 0.17 | 0.65 | 0.43 |
| 九、综合收益总额 | 30,325,906.98 | 13,260,903.85 | 50,750,223.4 | 33,329,362.29 |
| 归属于母公司股东的综合收益总额 | 30,325,906.98 | 13,260,903.85 | 50,750,223.4 | 33,329,362.29 |
| 公告日期 | 2025-08-21 | 2025-04-25 | 2025-04-25 | 2024-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |